Literature DB >> 6467679

Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis.

C A Penning, J Cunningham, M A French, G Harrison, N R Rowell, P Hughes.   

Abstract

Sera from 39 patients with systemic sclerosis were examined for a cytotoxic effect on human umbilical vein endothelium. Although none of the sera produced direct cytotoxicity of 51Cr-labelled endothelial cells, even with added complement, nine sera did produce increased 51Cr release when co-cultured with endothelial cells and normal human peripheral blood mononuclear cells. The effector cells involved in this cytotoxicity possessed Fc receptors but were non-T and non-adherent while the responsible serum factor(s) was present in IgG containing fractions. This cytotoxicity tended to occur in patients with both circulating immune complexes and precipitating antibodies to nuclear and cytoplasmic antigens who, as a group, had more severe and extensive visceral disease than those without such serological abnormalities. Control studies using sera from both 27 normal controls and 19 patients with either diabetes or extensive athero-sclerotic vascular disease failed to reveal any similar cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467679      PMCID: PMC1536266     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  ANTINUCLEAR AND PRECIPITATING AUTOANTIBODIES IN PROGRESSIVE SYSTEMIC SCLEROSIS.

Authors:  J S BECK; J R ANDERSON; K G GRAY; N R ROWELL
Journal:  Lancet       Date:  1963-12-07       Impact factor: 79.321

2.  The specificity of human autoantibodies that react with both cell nuclei and plasma membranes: the nuclear antigen is present on core mononucleosomes.

Authors:  O P Rekvig; K Hannestad
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

3.  Antibody in the induction and inhibition of lymphocyte cytotoxicity.

Authors:  I C MacLennan
Journal:  Transplant Rev       Date:  1972

4.  The association of HLA-B8 with visceral disease in systemic sclerosis.

Authors:  P Hughes; K Gelsthorpe; R W Doughty; N R Rowell; F D Rosenthal; I B Sneddon
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

5.  Detection of circulating immune complexes in some skin diseases by platelet aggregation test.

Authors:  K Yanase; S Imamura
Journal:  Br J Dermatol       Date:  1979-02       Impact factor: 9.302

6.  Plasmapheresis and immunosuppressive drug therapy in scleroderma.

Authors:  P C Dau; M B Kahaleh; R W Sagebiel
Journal:  Arthritis Rheum       Date:  1981-09

7.  Immune complexes in peripheral blood polymorphonuclear leucocytes of patients with Raynaud's phenomenon.

Authors:  J van der Maulen; A A Wouda; E Mandema; T H The
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

8.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06

Review 9.  Vascular disease in progressive systemic sclerosis (scleroderma).

Authors:  W L Norton; J M Nardo
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

10.  Endothelial injury in scleroderma.

Authors:  M B Kahaleh; G K Sherer; E C LeRoy
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

View more
  26 in total

Review 1.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  Y Renaudineau; R Revelen; Y Levy; K Salojin; B Gilburg; Y Shoenfeld; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  The effects of scleroderma sera on endothelial cell survival in vitro.

Authors:  T Etoh; A Igarashi; K Iozumi; Y Ishibashi; K Takehara
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

Review 3.  Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies.

Authors:  M J Dillon; E J Tizard
Journal:  Pediatr Nephrol       Date:  1991-03       Impact factor: 3.714

4.  Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma.

Authors:  R Sgonc; M S Gruschwitz; H Dietrich; H Recheis; M E Gershwin; G Wick
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies.

Authors:  C O Savage; B E Pottinger; G Gaskin; C M Lockwood; C D Pusey; J D Pearson
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 6.  The endothelium: its role in scleroderma.

Authors:  J D Pearson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

7.  Antibodies to mouse laminin in patients with systemic sclerosis (scleroderma) recognize galactosyl (alpha 1-3)-galactose epitopes.

Authors:  A Gabrielli; M Candela; A M Ricciatti; M L Caniglia; J Wieslander
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

8.  Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sjögren's syndrome.

Authors:  M Hebbar; P Lassalle; Y Delneste; P Y Hatron; B Devulder; A B Tonnel; A Janin
Journal:  Ann Rheum Dis       Date:  1997-04       Impact factor: 19.103

9.  Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods.

Authors:  S Majewski; M Błaszczyk; S Jabłonska; L Rudnicka; M Waşik; A Skiendzielewska; B Makieła
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

10.  Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration.

Authors:  M Blank; Y Tomer; M Stein; J Kopolovic; A Wiik; P L Meroni; G Conforti; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.